Researchers at NuraLogix have developed a new technology which can predict a person’s risk of pre-diabetes in just 30 seconds through facial blood flow patterns.
A pioneer in contactless health monitoring, Nuralogix, has developed new technology, with the ability to perform metabolic and blood biomarker health risk assessments for various chronic conditions through its Anura platform.
Anura™ is the only video-based contactless health monitoring solution that can measure vital signs and provide health risk assessments, using the firm’s patented Transdermal Optical Imaging (TOI™) technology.
As a first for video-based contactless health monitoring, the new capabilities add to the existing health and wellness measurements* Anura™ can assess from a 30-second video selfie, including the ability to accurately measure blood pressure.
The metabolic and blood biomarker risk assessments will join the existing cardiovascular disease risk assessments, including 10-year predictions of risk of death from heart attack or stroke.
Founded in 2015, NuraLogix’s ground-breaking technology allows third-party clients such as health providers, product developers, insurance companies, and wellness programs to help consumers better manage their physical and mental health.
How it works
NuraLogix delivers contactless health monitoring via its Anura™ platform that combines data gathered through its TOI™ technology, a novel form of Remote Photoplethysmography (rPPG).
Developed with data from more than 40,000 patients with multiple conditions, NuraLogix’s research on these predicted models has been tested and published in numerous peer-reviewed journals worldwide.
Anura™ uses a conventional video camera to extract facial blood flow information combined with sophisticated AI model analysis in the cloud that extrapolates health information from the pattern of facial blood flows.
Results are delivered within its intuitive app, showing information on over 30 health parameters* such as heart rate, breathing rate, and cuff-less blood pressure, and providing health risk assessments for some of the most prevalent chronic conditions.
This includes type 2 diabetes, hypertension, cardiovascular disease, and mental health.
Dr Keith Thompson, chief medical officer at NuraLogix, commented: “Following years of research and development, we are excited to share the expanded capabilities of the Anura™ platform. Our research models have been proven to predict whether a subject’s HbA1c is greater than 5.7 per cent, or their Fasting Blood Glucose is greater than 5.5mmol/L, to a clinically accurate level.
“The ability to assess health with just a look into every day, readily available consumer devices is a game changer for the healthcare industry.
“Using ubiquitous devices, Anura™ has the potential to accelerate the adoption of solutions for the early detection of chronic diseases, expand health equity and access to underserved populations while dramatically decreasing costs of care.”
